Physician profile
Kellie Frissora
NPI 1245857762
$847.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $829 · 2022: $18.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.99 | 2021-2022 | |
| Novo Nordisk INC | $119.12 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.62 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.17 | 2021 | |
| Lilly USA, LLC | $56.64 | 2021 | |
| Arbor Pharmaceuticals, INC. | $40.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.63 | 2021 | |
| Dexcom, INC. | $24.41 | 2021 | |
| Hologic Sales and Service, LLC | $19.53 | 2021 | |
| Therapeuticsmd, INC. | $19.22 | 2021 | |
| Exeltis, USA INC. | $18.71 | 2021 | |
| Esperion Therapeutics, INC. | $16.92 | 2021 | |
| Phadia US INC. | $16.32 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Frissora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.